Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06982469Recruiting
High-dose radiation for prostate cancer return after surgery
This trial tests a high-dose radiation treatment (brachytherapy) that places tiny radioactive seeds directly into the area where your prostate was. It is for men whose prostate cancer has returned only in that area after having their prostate removed.
Pamplona, Foral Community of NavarreAges 18–80 - NCT06980025RecruitingPhase 3
Aspirin dose trial to prevent preterm birth
This study tests if a higher dose of aspirin can help prevent another early delivery in women who have had a preterm birth before. If you qualify, you would take either a standard or escalated dose of aspirin during your current pregnancy.
Birmingham, AlabamaAges 14 years+ - NCT06965114RecruitingPhase 1/Phase 2
Testing tovorafenib plus rituximab for hairy cell leukemia
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
Bethesda, MarylandAges 18 years+ - NCT06967610RecruitingPhase 2
Pirtobrutinib, venetoclax, and obinutuzumab for recurrent CLL/SLL
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Houston, TexasAges 18 years+ - NCT06963905RecruitingPhase 1/Phase 2
Testing a combination drug for triple-negative breast cancer
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06970145RecruitingPhase 1/Phase 2
Anlotinib for recurrent craniopharyngioma
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Guangzhou, GuangdongAges 18–75 - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06954610Recruiting
Heart Check for Stroke Risk in Atrial Fibrillation
This trial uses heart imaging to better understand stroke risk in people with atrial fibrillation (an irregular heartbeat). It may help doctors decide on the best treatment to prevent another stroke.
BernAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06952868RecruitingPhase 2
BNCT for recurrent head and neck cancer
This trial tests a special type of radiation therapy called BNCT (boron neutron capture therapy) for head and neck cancers that have come back and cannot be removed by surgery. It may be an option for patients who have already had radiation and cannot receive standard chemotherapy.
Chiayi CityAges 18–80 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT06951503RecruitingPhase 3
AK112 plus chemo for first-line metastatic colorectal cancer
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
Guanzhou, GuangdongAges 18–75 - NCT06941363Recruiting
Salvage radiotherapy for prostate cancer recurrence after surgery
This study tests a very short course of radiation given after prostate surgery, specifically for men whose PSA is rising again. The goal is to see if this approach can safely control the cancer.
Monza, ItalyAges 18–90 - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+ - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT06159764Recruiting
Registry of nerve-targeting heart treatment for fainting
This registry tracks people who receive a heart procedure called cardioneuroablation to stop severe fainting spells. The procedure targets nerve signals that cause the heart to pause, and researchers want to learn how well it works in real-world patients.
BronAges 18–100 - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+ - NCT06930157RecruitingPhase 4
Shenling Baishu Granule to prevent low-risk colon polyp return
This study tests if a Chinese herbal medicine (Shenling Baishu Granule) can help prevent low-risk colon polyps from coming back after they've been removed. It is for people who have had a good colonoscopy and had their polyps taken out within the last 3 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06931821Recruiting
Mapping to guide ablation for ventricular tachycardia
This study tests a new way to map the heart's electrical activity to guide a procedure that destroys the tissue causing fast, dangerous heart rhythms. It's for people with heart disease and ventricular tachycardia that hasn't been controlled by medication.
Phoenix, ArizonaAges 18 years+ - NCT06925061RecruitingPhase 2
Testing EXL01 to prevent Crohn's disease return after surgery
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
Clermont-FerrandAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06487780Recruiting
Preventing foot ulcers with a lifestyle program
This trial tests whether a lifestyle program can help people with diabetes avoid new foot ulcers. If you've healed from a foot ulcer in the last year, you may be able to join.
Downey, CaliforniaAges 21 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.